...
首页> 外文期刊>Journal of Clinical and Diagnostic Research >The Beta Lactam Antibiotics as an Empirical Therapy in a Developing Country: An Update on Their Current Status and Recommendations to Counter the Resistance against Them
【24h】

The Beta Lactam Antibiotics as an Empirical Therapy in a Developing Country: An Update on Their Current Status and Recommendations to Counter the Resistance against Them

机译:Beta Lactam抗生素作为发展中国家的一种经验疗法:其现状更新和抗药性的建议

获取原文
           

摘要

In a developing country like India, where the patients have to bear the cost of their healthcare, the microbiological culture and the sensitivity testing of each and every infection is not feasible. Moreover, there are lacunae in the data storage, management and the sharing of knowledge with respect to the microorganisms which are prevalent in the local geographical area and with respect to the antibiotics which are effective against them. Thus, an empirical therapy for treating infections is imperative in such a setting. The beta lactam antibiotics have been widely used for the empirical treatment of infections since the the discovery of penicillin. Many generations of beta lactams have been launched with, the claims of a higher sensitivity and less resistance, but their sensitivities have drastically decreased over time. Thus, the preference for beta lactams, especially the cephalosporins, as an empirical therapy, among the prescribers was justified initially, but the current sensitivity patterns do not support their empirical use in hospital and community acquired infections. There is a need for increasing the awareness and the attitudinal change among the prescribers, screening of the antibiotic prescriptions, the strict implementation of antibiotic policies in hospital settings, restricting the hospital supplies and avoiding the prescriptions of beta lactams, a regular census of the local sensitivity patterns to formulate and update the antibiotic policies, upgradation of the laboratory facilities for a better and faster detection of the isolates, proper collection, analyses and sharing of the data and the encouragement of the research and development of newer antibiotics with novel mechanisms of action.
机译:在像印度这样的发展中国家,病人必须承担医疗费用,因此对每种感染的微生物培养和敏感性测试都是不可行的。此外,关于在本地地理区域中普遍存在的微生物以及对它们有效的抗生素的数据存储,管理和知识共享方面存在空白。因此,在这种情况下,治疗感染的经验疗法势在必行。自发现青霉素以来,β内酰胺抗生素已广泛用于经验性感染治疗。已经推出了许多世代的β-内酰胺,声称具有更高的敏感性和更低的抵抗力,但随着时间的流逝,它们的敏感性急剧下降。因此,开处方者开始偏爱使用β-内酰胺,尤其是头孢菌素作为经验疗法是合理的,但目前的敏感性模式并不支持其在医院和社区获得性感染中的经验使用。有必要提高处方者的认识和态度变化,筛选抗生素处方,在医院环境中严格执行抗生素政策,限制医院供应,避免使用β-内酰胺处方,当地定期普查制定和更新抗生素政策的敏感性模式,实验室设施的升级,以便更好,更快地检测到分离物,正确收集,分析和共享数据,并鼓励研究和开发具有新作用机制的新型抗生素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号